Pfizer Inc ($NYSE:PFE)., one of the world’s largest pharmaceutical companies, suffered a 0.99% decrease of its stock price on Thursday, reaching a close at $35.00. This marked the lowest closing price for the day during a trading session that was overall negative. The company’s portfolio is divided into five main divisions: Primary Care, Specialty Care, Established Products and Emerging Markets, International Brands and Animal Health.
Its products range from prescription drugs and vaccines to consumer health products, animal health products and biologic products. The company is best known for its research and development of innovative medications, including Viagra, Celebrex and Lipitor, as well as its commitment to corporate social responsibility initiatives.
Analysis – Pfizer Inc Intrinsic Value Calculator
GoodWhale has conducted an analysis on the wellbeing of PFIZER INC, a publicly traded company. After careful assessment, our proprietary Valuation Line resulted in a fair value of around $46.1 per PFIZER INC share. Currently, PFIZER INC stock is traded at $35.0, which is 24.1% lower than its fair value. This is an indication that the stock is undervalued in the market and presents an opportunity for investment. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Pfizer Inc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Pfizer Inc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Pfizer Inc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Pfizer Inc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
In the pharmaceutical industry, competition is fierce between companies striving to bring innovative new drugs to market. Among the leaders in this industry are Pfizer Inc and its competitors Astellas Pharma Inc, Roche Holding AG, and AstraZeneca PLC. While each company has its own strengths and weaknesses, they all share a commitment to research and development in an effort to stay ahead of the competition.
– Astellas Pharma Inc ($TSE:4503)
Astellas Pharma Inc is a Japanese pharmaceutical company with a market cap of 3.61T as of 2022. The company’s ROE is 6.6%. Astellas Pharma is engaged in the research, development, manufacture, and marketing of pharmaceutical products. The company’s products include ethical drugs, over-the-counter drugs, and generic drugs. Astellas Pharma also has a clinical research division that conducts clinical trials of new drugs.
Roche Holding AG is a multinational pharmaceutical company headquartered in Basel, Switzerland. The company was founded in 1896 by Fritz Hoffmann-La Roche. Roche is the world’s largest biotech company, with products in the areas of pharmaceuticals, diagnostics, and consumer health. The company’s mission is to “improve lives by enabling people to do more, feel better, and live longer.”
Roche Holding AG has a market cap of 270.34B as of 2022, a Return on Equity of 47.83%. The company’s strong market position and financial performance are due to its innovative products and services, which address a broad range of medical needs. Roche is committed to research and development, and has a strong pipeline of new products in development. The company’s focus on customer needs and its ability to bring new products to market quickly have resulted in strong financial performance and shareholder value.
– AstraZeneca PLC ($LSE:AZN)
AstraZeneca PLC is a pharmaceutical company with a market cap of 152.81 billion as of 2022. The company has a return on equity of -0.94%. AstraZeneca PLC is engaged in the research, development, manufacture, and marketing of prescription pharmaceuticals and biologic products for the treatment of cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory diseases.
Pfizer Inc. has recently seen a downturn in stock prices, dropping 0.99% to $35.00 on Thursday. This decline in stock price can be attributed to the overall market negativity from investors. Analysts recommend monitoring the stock closely, as the company continues to release financial results and make strategic decisions. It may be a good time to consider selling or buying shares, depending on the investor’s risk appetite and market outlook. Understanding the fundamentals of a company is essential when making investment decisions, such as assessing profitability, liquidity and debt ratios.
Additionally, investors should keep an eye on macroeconomic events, such as changes in fiscal policies or economic trends. Ultimately, investors should always review their own financial goals and make decisions that best align with long-term financial objectives.